L-carnitine - More than just a supportive therapy in the treatment of advanced pancreas carcinoma? (CARPAN trial);L-Carnitin - mehr als nur eine supportive Therapie in der Behandlung des fortgeschrittenen Pankreaskarzinoms? (CARPAN-Studie)

Deutsche Zeitschrift fur Onkologie

Volumn 44, Issue 3, 2012, Pages 103-108

  Kraft, Matthias ^b   Kraft, Kathleen ^b   Lerch, Markus M ^a  

^a UNIVERSITY OF GREIFSWALD   (Germany)

^b NONE

Author keywords

cancer cachexia; fatique syndrome; L Carnitine; Pancreatic adenocarcinoma; quality of life

Indexed keywords

CARNITINE; PLACEBO;

ADVANCED CANCER; ARTICLE; CACHEXIA; CANCER FATIGUE; CANCER MORTALITY; HOSPITALIZATION; HUMAN; MALNUTRITION; NUTRITIONAL STATUS; PANCREAS CARCINOMA; QUALITY OF LIFE; SURVIVAL RATE; UNSPECIFIED SIDE EFFECT;

EID: 84866539216     PISSN: 16175891     EISSN: 14390930     Source Type: Journal    
DOI: 10.1055/s-0032-1314696     Document Type: Article

References (26)

1. Bachmann J., Ketterer K., Marsch C. et al. Pancreatic cancer related cachexia: influence on metabolism and correlation to weight loss and pulmonary function. BMC Cancer: 2009; 9 255
2. Batzler W. Krebs in Deutschland Häufigkeiten und Trends. Arbeitsgemeinschaft Bevölkerungsbezogener Krebsregister in Deutschland in Zusammenarbeit mit dem Robert Koch Institut. 2002 32 35
3. Beger H. G., Rau B., Gansauge F. et al. Pancreatic cancer-low survival rates. Dtsch Arztebl Int: 2008; 105(14) 255 62
4. Bosy-Westphal A., Danielzik S., Dorhofer R. P. et al. Phase angle from bioelectrical impedance analysis: population reference values by age, sex, and body mass index. J Parenter Enteral Nutr: 2006; 30 309 316
5. Burris H. A. III, Moore M. J., Andersen J. et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol: 1997; 15 2403 2413 (Pubitemid 27251144)
6. Cruciani R. A., Dvorkin E., Homel P. et al. L-carnitine supplementation in patients with advanced cancer and carnitine deficiency: a double-blind, placebo-controlled study. J Pain Symptom Manage: 2009; 37 622 631
7. Dalla Libera L., Sabbadini R., Renken C. et al. Apoptosis in the skeletal muscle of rats with heart failure is associated with increased serum levels of TNF-alpha and sphingosine. J Mol Cell Cardiol: 2001; 33(10) 1871 8 (Pubitemid 32977139)
8. Dodson W. L., Sachan D. S., Krauss S., Hanna W. Alterations of serum and urinary carnitine profiles in cancer patients: hypothesis of possible significance. J Am Coll Nutr: 1989; 8 133 142 (Pubitemid 20047675)
9. Fitzsimmons D., Johnson C. D., George S. et al. Development of a disease specific quality of life (QoL) questionnaire module to supplement the EORTC core cancer QoL questionnaire, the QLQ-C30 in patients with pancreatic cancer. EORTC Study Group on Quality of Life. Eur J Cancer: 1999; 35 939 941 (Pubitemid 29277128)
10. Grazi G., Meriggioli M., Donati G. Can the treatment with L-carnitine improve the inflammation in chronic hemodialysis patients? G Ital Nefrol: 2004; 21 Suppl 30 204 207
11. Greenlee R. T., Hill-Harmon M. B., Murray T., Thun M. Cancer statistics 2001. Cancer J Clin: 2001; 51 15 36
12. Kaplan E. L., Meier P. Nonparametric estimation from incomplete observation. Journal of the American Statistical Association: 1958; 53 457 481
13. Kodo N., Millington D. S., Norwood D. L., Roe C. R. Quantitative assay of free and total carnitine using tandem mass spectrometry. Clin Chim Acta: 1990; 186 383 390 (Pubitemid 20040322)
14. Kraft M., Kraft K., Gärtner S. et al. L-Carnitine-supplementation in advanced pancreatic cancer (CARPAN) - a randomized multicentre trial. Nutr J: 2012; 11(1) 52 [Epub ahead of print]
15. Lancaster C. S., Hu C., Franke R. M. et al. Cisplatin-induced downregulation of OCTN2 affects carnitine wasting. Clin Cancer Res: 2010; 16 4789 4799
16. Lebrun C., Alchaar H., Candito M. et al. Levocarnitine administration in multiple sclerosis patients with immunosuppressive therapy-induced fatigue. Mult Scler: 2006; 12 321 324 (Pubitemid 43827187)
17. Li D., Morris J. S., Liu L. et al. Body mass index and risk, age of onset, and survival in patients with pancreatic cancer. JAMA: 2009; 301(24) 2553 62
18. Longo L. Harrisons Kompendium Innere Medizin: Hämatologie und Onkologie. London McGraw-Hill International (UK) Ltd.: 2000; 387
19. Mancinelli A., DIddio S., Bisonni R. et al. Urinary excretion of L-carnitine and its short-chain acetyl-L-carnitine in patients undergoing carboplatin treatment. Cancer Chemother Pharmacol: 2007; 60 19 26 (Pubitemid 46643713)
20. Marthaler N. P., Visarius T., Küpfer A., Lauterburg B. H. Increased urinary losses of carnitine during ifosfamide chemotherapy. Cancer Chemother Pharmacol: 1999; 44(2) 170 172 (Pubitemid 29297065)
21. Neoptolemos J. P., Stocken D. D., Bassi C. et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA: 2010; 304 1073 1081
22. Nitenberg G., Raynard B. Nutritional support of the cancer patient: issues and dilemmas. Crit Rev Oncol Hematol: 2000; 34 137 168 (Pubitemid 30320960)
23. Radbruch L., Sabatowski R., Elsner F. et al. Validation of the German version of the brief fatigue inventory. J Pain Symptom Manage: 2003; 25 449 458 (Pubitemid 36506674)
24. Rocha-Lima C. M. New directions in the management of advanced pancreatic cancer: a review. Anticancer Drugs: 2008; 19 435 446 (Pubitemid 351556396)
25. Van Cutsem E., Vervenne W. L., Bennouna J. et al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol: 2009; 27(13) 2231 7
26. Vescovo G., Ravara B., Gobbo V. et al. L-Carnitine: a potential treatment for blocking apoptosis and preventing skeletal muscle myopathy in heart failure. Am J Physiol Cell Physiol: 2002; 283(3) 802 810